ABSTRACT
myo-Inositol, 500 mg twice a day, given to seven diabetic patients for two weeks, increased the amplitude of the evoked action potentials of the median, sural, and popliteal nerves by an average of 76%, 160%, and 40%, respectively. There was no significant change in the conduction velocities of these nerves, myo-Inositol may be valuable in the treatment of diabetic neuropathy.
Subject(s)
Diabetes Mellitus/physiopathology , Diabetic Neuropathies/drug therapy , Inositol/pharmacology , Peripheral Nerves/drug effects , Aged , Clinical Trials as Topic , Dose-Response Relationship, Drug , Double-Blind Method , Drug Evaluation , Evoked Potentials/drug effects , Humans , Inositol/administration & dosage , Inositol/therapeutic use , Lumbosacral Plexus/physiopathology , Median Nerve/physiopathology , Middle Aged , Neural Conduction/drug effects , Peripheral Nerves/physiopathology , Placebos , Sural Nerve/physiopathologyABSTRACT
In pregnancies with a normal outcome the oestrogen:creatinine ratio in early morning samples of urine showed a smaller day-to-day variation than the ratio in 24-h urine or the 24-h total oestrogen excretion, and a significant fall could be detected more easily. Patients admitted to hospital who eventually delivered a healthy baby provided a reference range which, after logarithmic transformation, increased linearly with period of gestation. A fall in log10 oestrogen:creatinine ratio exceeding 40% of this range is unusual in pregnancies with a healthy outcome, and suggest impaired fetoplacental function.
Subject(s)
Creatinine/urine , Estrogens/urine , Fetus/physiology , Placenta/physiology , Female , Gestational Age , Humans , Monitoring, Physiologic , Pregnancy , Time FactorsSubject(s)
Clinical Laboratory Techniques/methods , Drug-Related Side Effects and Adverse Reactions , Albuterol/adverse effects , Biochemistry , Computers , Humans , Hyperkalemia/chemically induced , Male , Middle Aged , Patient Care Team , Pharmacists , Pharmacy and Therapeutics Committee , Safety , United Kingdom , WorkforceABSTRACT
In a series of patients with chronic renal failure managed conservatively, the rise in the plasma-myo-inositol (myoinositol) concentration has been found to be related to depression of sural-nerve conduction velocity. There was no correlation with motor-nerve conduction velocity in the peroneal nerve, or with either of these variables in a series of patients receiving chronic haemodialysis. Despite the negative correlation with sural-nerve conduction velocity, there was no correlation between the plasma-myoinositol concentration and the presence of peripheral neuropathy as assessed clinically. It is concluded that hypermyoinositolaemia may depress nerve conduction velocity, but there is no evidence that it is responsible for the development of uraemic polyneuropathy.
Subject(s)
Inositol/blood , Peripheral Nervous System Diseases/etiology , Uremia/complications , Action Potentials , Humans , Kidney Failure, Chronic/complications , Motor Neurons/physiology , Muscles/innervation , Neural Conduction , Peripheral Nervous System Diseases/blood , Peripheral Nervous System Diseases/physiopathology , Peroneal Nerve/physiopathology , Renal Dialysis , Sural Nerve/physiopathology , Uremia/blood , Uremia/therapySubject(s)
Alanine Transaminase/blood , Heparin/therapeutic use , Renal Dialysis , Heparin/pharmacology , HumansABSTRACT
A case of bilateral phaeochromocytoma with catecholamine-induced myocarditis is described. The two operations needed allowed comparison of the use of alpha-methyl-p-tyrosine alone and in conjunction with adrenergic blocks in the management of the patient. The combination of both drugs was particularly successful in the relief of symptoms and reduction of catecholamine metabolism as monitored by 4-hydroxy-3-methoxymandelic acid (HMMA) excretion. As myocarditis is a potentially fatal complication, further investigation of the combined use of alpha-methyl-p-tyrosine and adrenergic blocking drugs is suggested in the pre-operative management of patients with phaeochromocytoma.
